<DOC>
	<DOCNO>NCT02711956</DOCNO>
	<brief_summary>This open label , non-randomized , Phase 1b , dose escalation dose confirmation study ZEN003694 combination enzalutamide patient mCRPC .</brief_summary>
	<brief_title>A Study ZEN003694 Combination With Enzalutamide Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Males age ≥ 18 year 2 . Metastatic , castrate resistant , histologically confirm prostate cancer ; surgically castrate continuous medical castration ≥ 8 week prior screen 3 . Serum testosterone &lt; 50 ng/dL determine within 4 week first administration study drug 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 5 . Adequate laboratory parameter [ absolute neutrophil ( ANC ) , platelet , asparate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin , creatinine coagulation parameter ] screen 6 . Dose Escalation : Enzalutamidenaïve patient follow prior progression abiraterone PCWG2 criterion within 12 week discontinue abiraterone 7 . Dose Confirmation Cohort A ( DCA ) : Currently receive enzalutamide recent systemic therapy mCRPC experience PSA progression PCWG2 criterion absence radiographic and/or clinical progression . Patients may may experience prior progression abiraterone . 8 . Dose Confirmation Cohort B ( DCB ) : Enzalutamidenaïve patient follow prior progression abiraterone PCWG2 criterion within 12 week discontinue abiraterone 1 . Any history brain metastasis prior seizure condition predispose seizure activity 2 . Have previously receive investigational BET inhibitor ( include previous participation study Study ZEN003694001 ) 3 . Have receive prior systemic anticancer therapy ( include abiraterone ) investigational therapy within 2 week five halflives , whichever short , prior first administration study drug 4 . Failure recover Grade 1 low toxicity relate prior systemic therapy ( exclude alopecia neuropathy ) prior study entry 5 . Radiation therapy within 2 week first administration study drug 6 . Have receive prior chemotherapy metastatic castrationresistant setting ( prior chemotherapy hormonesensitive setting allow provide last dose least 6 month prior study entry ) 7 . Have receive prior investigational antiandrogen therapy , include ARN509 8 . Currently receive medication know strong inhibitor CYP2C8 , strong inducer ( except enzalutamide ) inhibitor CYP3A4 substrates CYP3A4 , CYP2C9 CYP2C19 narrow therapeutic window . Strong inducer , inhibitor substrate must discontinue least 7 day prior first administration study drug . 9 . Not candidate enzalutamide treatment , opinion Investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Castration-Resistant Prostate Cancer ( mCRPC )</keyword>
	<keyword>Phase 1b</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Pharmacokinetics ( PK )</keyword>
	<keyword>ZEN003694</keyword>
	<keyword>ZEN-3694</keyword>
	<keyword>Metastatic Castrate-Resistant Prostate Cancer</keyword>
	<keyword>BET inhibitor ( BETi )</keyword>
	<keyword>Bromodomain</keyword>
	<keyword>Pharmacodynamics ( PD )</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>XTANDI</keyword>
	<keyword>MDV3100</keyword>
	<keyword>Epigenetics</keyword>
</DOC>